Skip to main content
SGHT logo

SGHT · Sight Sciences, Inc.

Track SGHT — free
$10.64 -0.19 (-1.75%)
Market Cap
$601.92M
Shares
55.58M
Volume · Nov 16 59.08K Avg daily vol (3M) 314.3K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.83 Open$11.02 Day$10.75–11.13 52W close$3.45–11.01 Avg vol 30d386K Short int1.1M · 2.0% of shares · 4.3d Short vol17% Last earningsNov 4, 2026 DataJul 2021–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 3, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 4
Earnings call
Revenue Guidance Raised to $92 to $93 Million

Sight Sciences reported record revenue of $24.9 million, growing 25% year over year, and raised full-year 2026 revenue guidance to $92 to $93 million while maintaining adjusted operating expense guidance of $92 to $94 million.

4 source passages
Earlier today, Sight Sciences released financial results for the third quarter, ended September 30th, 2026, raised its revenue guidance, and maintained its adjusted operating expense guidance for the full year 2026. We are extremely proud of our results again this quarter, where we reported record revenue of $24.9 million, growing 25% year over year. We are raising total revenue guidance to $92 to $93 million, up from $88 to $92 million. We are maintaining adjusted operating expense guidance of $92 to $94 million, representing full-year growth of 5% to 7% compared to prior year. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month revenue rose 19.4% as net loss narrowed

Sight Sciences reported nine-month revenue of $68.0 million, up 19.4%, and a net loss of $24.2 million versus $34.3 million. Cash and cash equivalents totaled $77.4 million as of September 30, 2026.

Revenue $24.92M ▲ 25.2% Net loss $6.81M Diluted EPS -$0.12
Read from the MD&A section
5 source passages
For the nine months ended September 30, 2026, revenue was $68.0 million, an increase of $11.0 million, or 19.4% compared to $57.0 million in the prior year comparable period. Net cash used in operating activities for the nine months ended September 30, 2026 was $15.1 million, consisting primarily of a net loss of $24.2 million, as well as a net change in our operating assets and liabilities of $0.9 million. Net cash used in operating activities for the nine months ended September 30, 2025 was $27.9 million, consisting primarily of a net loss of $34.3 million, as well as a net change in our operating assets and liabilities of $5.9 million, partially offset by non-cash charges of $12.0 million. As of September 30, 2026, we had cash and cash equivalents of $77.4 million, an accumulated deficit of $409.0 million, and an outstanding term loan balance of $40.0 million plus a $2.4 million final payment due at maturity under the Hercules Loan Agreement (excluding unamortized debt discount and issuance costs). Sight Sciences’ mission is to transform possibility into practice with accessible, interventional technologies and trusted partnerships with eyecare providers, with a vision of making interventional eyecare the standard of care so every patient can be treated earlier, more effectively, and with lasting outcomes. Open the document at this passage
Nov 4
Current report 8-K
Raises 2026 Revenue Guidance After 25% Quarterly Revenue Growth

Sight Sciences reported third-quarter revenue of $24.9 million, up 25%, and raised full-year 2026 revenue guidance to $92 million to $93 million from $88 million to $92 million. Cash usage fell 74% to $2.4 million.

Financial results, Regulation FD disclosure
4 source passages
Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2026. Record revenue of $24.9 million in the third quarter of 2026, a 25% increase compared to $19.9 million in the third quarter of 2025. Cash and cash equivalents totaled $77.4 million as of September 30, 2026. Cash usage was $2.4 million in the third quarter of 2026, down 74% compared to the same period in the prior year. Sight Sciences raised its revenue guidance for full year 2026 to range from $92 million to $93 million, representing year-over-year growth of 19% to 20%, versus prior revenue guidance of $88 million to $92 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$88.39M
Trailing 12 months
Net income (TTM)
−$28.40M
Trailing 12 months
Revenue growth YoY
+25.2%
Year over year
Operating margin
-29.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$36.37M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.2%
Year over year · more shares
Price change (1Y)
+53.6%
Trailing year
Short interest
2.0%
Latest settlement · 4.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised full-year 2026 revenue guidance to $92 million-$93 million. IDE and IG advanced, OMNI Ultra launched, IDE gross margin improved, and cash burn fell 74%, while operating expenses increased and early-stage IDE forecasting, market-access timing, and broader business risks remain.

Bullish
  • + Third-quarter revenue rose 25% to a record $24.9 million, extending the company's return to double-digit growth. new
  • + Management raised full-year 2026 revenue guidance to $92 million-$93 million and increased the IDE outlook to approximately $12 million. new
  • + IDE gross margin increased to 79% from 38% in the prior-year period, primarily because of higher average selling prices. new
Bearish
  • − Adjusted operating expenses increased 21% to $24.0 million as the company invested in growth in both segments. new
  • − The timing of additional TierCare fee schedules and payer coverage decisions remains uncertain and outside the company's control. new
  • − TierCare guidance reflects the difficulty of forecasting the business because it remains in the early stages of market development. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +75%
above
Price vs 50-day avg +21%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 98%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +31%
trailing
6-month return +117%
trailing
YTD return +37%
this year
Relative strength +117%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow Distributing
90 of 112 funds reported for Sep 30 · net -271.9K sh shares · +17 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.04% of shares out · ▼ -8.5% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
112 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Strong
Revenue growth −3%
Y/Y
Gross margin 86%
expanding
EPS growth +28%
Y/Y
Free cash flow $-29.9M
Balance sheet $51.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −62%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the Earnings Call filed Aug 5, 2026
Total revenue guidance · full year 2026 Raised $88M – $92M
May 6, 2026 $83M – $89M changed to Aug 5, 2026 $88M – $92M
prior FY $77.36M midpoint +16.3% Y/Y
Interventional glaucoma revenue guidance · full year 2026 Raised $79M – $81M
Mar 4, 2026 $77M – $81M changed to Aug 5, 2026 $79M – $81M
Interventional dry eye revenue guidance · full year 2026 Initiated $9M – $11M
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Interventional Glaucoma segment revenue · full year 2026 $77M – $81M
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
Interventional dry eye revenue · third quarter 2026 $3M
Guided vs delivered · last 4 settled
Revenue full year 2025
guided $76M – $78M
$77.36M In line
Revenue full year 2023
guided $89M – $94M
$81.06M Miss −11.4%
Revenue full year 2022
guided $70M – $72M
$71.33M In line
Revenue full year 2021
guided $47.5M – $48.5M
$48.96M Beat +2.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+75% Bullish
Price vs 50-day avg
+21% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
98% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow Distributing
90 of 112 funds reported for Sep 30 · net -271.9K sh shares · +17 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.04% of shares out · ▼ -8.5% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
112 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $11 · 98% Range high $11
vs 200-day avg +75% vs 50-day avg +21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Operating Expenses non-GAAP 43.49M Six Months Ended June 30, 2026 —
Cash usage $5.2M Q2 2026 —
IDE patient lives added 4.1M Q2 2026 —
Interventional Dry Eye active customers 176 Three Months Ended June 30, 2026 —
Interventional Dry Eye lid treatment units sold 3,091 Three Months Ended June 30, 2026 —
Interventional Glaucoma active customers 1,214 Three Months Ended June 30, 2026 —
Total IDE patient lives with access to appropriate reimbursement 14.5M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SGHT
Sight Sciences, Inc.
this stock
$601.92M +36.6% -3.1% — 2.0%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
124
% held
39.4%
Reported
90 of 112
Top holder
Long Focus Capital Manage…
Held Float
View
Held by Funds
Fund positions
112
View
Short & Settlement
Short Interest Falling
Shares short
1.1M
Days to cover
4.3d
Change
-105.3K sh
View
Short Volume
Short vol %
17%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
9
Value
$75
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
33.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$77.4M
Net income (FY)
$-38.4M
EPS diluted
$-0.74
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
18

Sight Sciences reported nine-month revenue of $68.0 million, up 19.4%, and a net loss of $24.2 million versus $34.3 million. Cash and cash equivalents totaled $77.4 million as of September 30, 2026.

View
Proposed Sales
Value
$260.5K
Shares
26.0K
Filed
Nov 5, 2026
View
Exempt Offerings
Offering
$23.2M
Filed
Dec 10, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Sight Sciences to Report Third Qu…
Published
Oct 21, 2026
View

Performance

5D 20D 120D MTD YTD
SGHT +7.4% +30.8% +117.0% +16.2% +36.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +4.9% +32.0% +116.5% +16.4% +26.0%
Key facts CIK 1531177 CUSIP 82657M105 13F (30d) 92 filings 78 filers Visit website Investor relations